Pasithea Therapeutics Corp. (NASDAQ:KTTA) Short Interest Update

Pasithea Therapeutics Corp. (NASDAQ:KTTA) was the recipient of a significant drop in short interest in September. As of September 15th, there was short interest totalling 400 shares, a drop of 90.7% from the August 31st total of 4,300 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average trading volume of 17,100 shares, the days-to-cover ratio is presently 0.0 days.

Pasithea Therapeutics Price Performance

Shares of Pasithea Therapeutics stock traded down $0.17 during trading on Friday, hitting $5.68. 649,816 shares of the stock were exchanged, compared to its average volume of 334,684. The firm’s 50-day moving average price is $4.73 and its 200 day moving average price is $5.86. Pasithea Therapeutics has a 12-month low of $3.61 and a 12-month high of $17.40.

Pasithea Therapeutics (NASDAQ:KTTA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($3.71) earnings per share (EPS) for the quarter.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.